1. Lenders JWM, Eisenhofer G. Update on modern management of pheochromocytoma and paraganglioma. Endocrinol Metab (Seoul) 2017;32:152-161.
[CROSSREF] [PUBMED] [PMC]
2. Plouin PF, Duclos JM, Soppelsa F, Boublil G, Chatellier G. Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center. J Clin Endocrinol Metab 2001;86:1480-1486.
[CROSSREF] [PUBMED]
3. Khorram-Manesh A, Ahlman H, Nilsson O, Oden A, Jansson S. Mortality associated with pheochromocytoma in a large Swedish cohort. Eur J Surg Oncol 2004;30:556-559.
[CROSSREF] [PUBMED]
4. Prejbisz A, Lenders JW, Eisenhofer G, Januszewicz A. Cardiovascular manifestations of phaeochromocytoma. J Hypertens 2011;29:2049-2060.
[CROSSREF] [PUBMED]
5. Zelinka T, Petrak O, Turkova H, Holaj R, Strauch B, Krsek M, et al. High incidence of cardiovascular complications in pheochromocytoma. Horm Metab Res 2012;44:379-384.
[CROSSREF] [PUBMED] [PDF]
6. Kim KY, Kim JH, Hong AR, Seong MW, Lee KE, Kim SJ, et al. Disentangling of malignancy from benign pheochromocytomas/paragangliomas. PLoS One 2016;11:e0168413.
[CROSSREF] [PUBMED] [PMC]
7. Plouin PF, Fitzgerald P, Rich T, Ayala-Ramirez M, Perrier ND, Baudin E, et al. Metastatic pheochromocytoma and paraganglioma: focus on therapeutics. Horm Metab Res 2012;44:390-399.
[CROSSREF] [PUBMED] [PDF]
8. Hong AR, Kim JH, Park KS, Kim KY, Lee JH, Kong SH, et al. Optimal follow-up strategies for adrenal incidentalomas: reappraisal of the 2016 ESE-ENSAT guidelines in real clinical practice. Eur J Endocrinol 2017;177:475-483.
[CROSSREF] [PUBMED]
9. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000;85:637-644.
[PUBMED]
10. McNeil AR, Blok BH, Koelmeyer TD, Burke MP, Hilton JM. Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust N Z J Med 2000;30:648-652.
[CROSSREF] [PUBMED]
11. Berends AMA, Buitenwerf E, de Krijger RR, Veeger NJGM, van der Horst-Schrivers ANA, Links TP, et al. Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: a nationwide study and systematic review. Eur J Intern Med 2018;51:68-73.
[CROSSREF] [PUBMED]
12. Cheol Seong S, Kim YY, Khang YH, Heon Park J, Kang HJ, Lee H, et al. Data resource profile: the National Health Information Database of the National Health Insurance Service in South Korea. Int J Epidemiol 2017;46:799-800.
[CROSSREF] [PUBMED] [PDF]
13. Sinclair AM, Isles CG, Brown I, Cameron H, Murray GD, Robertson JW. Secondary hypertension in a blood pressure clinic. Arch Intern Med 1987;147:1289-1293.
[CROSSREF] [PUBMED]
14. Anderson GH Jr, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 1994;12:609-615.
[CROSSREF] [PUBMED]
15. Ariton M, Juan CS, AvRuskin TW. Pheochromocytoma: clinical observations from a Brooklyn tertiary hospital. Endocr Pract 2000;6:249-252.
[CROSSREF] [PUBMED] [PDF]
16. Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004;27:193-202.
[CROSSREF] [PUBMED]
17. Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 1983;58:802-804.
[PUBMED]
18. Guerrero MA, Schreinemakers JM, Vriens MR, Suh I, Hwang J, Shen WT, et al. Clinical spectrum of pheochromocytoma. J Am Coll Surg 2009;209:727-732.
[CROSSREF] [PUBMED]
19. Mesmar B, Poola-Kella S, Malek R. The physiology behind diabetes mellitus in patients with pheochromocytoma: a review of the literature. Endocr Pract 2017;23:999-1005.
[CROSSREF] [PUBMED]
20. Beninato T, Kluijfhout WP, Drake FT, Lim J, Kwon JS, Xiong M, et al. Resection of pheochromocytoma improves diabetes mellitus in the majority of patients. Ann Surg Oncol 2017;24:1208-1213.
[CROSSREF] [PUBMED] [PDF]
21. Kim BJ, Kwak MK, Ahn SH, Kim H, Lee SH, Song KH, et al. Lower bone mass and higher bone resorption in pheochromocytoma: importance of sympathetic activity on human bone. J Clin Endocrinol Metab 2017;102:2711-2718.
[CROSSREF] [PUBMED] [PDF]
22. Kim BJ, Lee SH, Koh JM. Bone health in adrenal disorders. Endocrinol Metab (Seoul) 2018;33:1-8.
[CROSSREF] [PUBMED] [PMC]
23. Hamidi O, Young WF Jr, Iniguez-Ariza NM, Kittah NE, Gruber L, Bancos C, et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. J Clin Endocrinol Metab 2017;102:3296-3305.
[CROSSREF] [PUBMED] [PMC] [PDF]
24. Choi YM, Sung TY, Kim WG, Lee JJ, Ryu JS, Kim TY, et al. Clinical course and prognostic factors in patients with malignant heochromocytoma and paraganglioma: a single institution experience. J Surg Oncol 2015;112:815-821.
[CROSSREF] [PUBMED]
25. Li ML, Fitzgerald PA, Price DC, Norton JA. Iatrogenic pheochromocytomatosis: a previously unreported result of laparoscopic adrenalectomy. Surgery 2001;130:1072-1077.
[CROSSREF] [PUBMED]
26. Bosca Robledo A, Ponce Marco JL, Belda Ibanez T, Meseguer Anastasio MF, Gomez Gavara C. Pheochromocytomatosis: a risk after pheochromocytoma surgery. Am Surg 2010;76:E122-E124.
[PUBMED]
27. Hamidi O, Young WF Jr, Gruber L, Smestad J, Yan Q, Ponce OJ, et al. Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 2017;87:440-450.
[CROSSREF] [PUBMED] [PMC]
28. Ayala-Ramirez M, Feng L, Johnson MM, Ejaz S, Habra MA, Rich T, et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. J Clin Endocrinol Metab 2011;96:717-725.
[CROSSREF] [PUBMED] [PDF]
29. Goffredo P, Sosa JA, Roman SA. Malignant pheochromocytoma and paraganglioma: a population level analysis of long-term survival over two decades. J Surg Oncol 2013;107:659-664.
[CROSSREF]